Lipsmeier, Florian
Taylor, Kirsten I.
Postuma, Ronald B.
Volkova-Volkmar, Ekaterina
Kilchenmann, Timothy
Mollenhauer, Brit
Bamdadian, Atieh
Popp, Werner L.
Cheng, Wei-Yi
Zhang, Yan-Ping
Wolf, Detlef
Schjodt-Eriksen, Jens
Boulay, Anne
Svoboda, Hanno
Zago, Wagner
Pagano, Gennaro
Lindemann, Michael
Article History
Received: 31 January 2022
Accepted: 30 June 2022
First Online: 15 July 2022
Competing interests
: The Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: FL, KIT, EVV, TK, AB, WLP, WC, YZ, DW, JSE, ABo, HS and GP reports personal fees from F. Hoffmann-La Roche Ltd. BM reports personal fees and other from F. Hoffmann-La Roche Ltd, during the conduct of the study; personal fees from Biogen, personal fees from Servier, non-financial support from Amprion, Grants and personal fees from Michael J. Fox Foundation for Parkinson's Research, Grants from DFG, Grants from EU (Horizon2020), Grants from Parkinson Fonds Deutschland, Grants from Hilde Ulrich Stiftung. WZ reports personal fees from F. Hoffmann-La Roche Ltd and Prothena Ltd. RBP reports Grants and personal fees from Fonds de la Recherche en Sante, Grants from Canadian Institute of Health Research, Grants from The Parkinson Society of Canada, Grants from Weston-Garfield Foundation, Grants from Michael J. Fox Foundation, Grants from Webster Foundation, Grants from National Institute of Health, Grants and personal fees from Roche, personal fees from Takeda, personal fees from Teva Neurosciences, personal fees from Biogen, personal fees from Boehringer Ingelheim, personal fees from Theranexus, personal fees from GE HealthCare, personal fees from Jazz Pharmaceuticals, personal fees from AbbVie, personal fees from Janssen, personal fees from Otsuko, personal fees from Phytopharmica, personal fees from Inception Sciences, other from Parkinson Canada, personal fees from Paladin. ML reports personal fees from F. Hoffmann-La Roche Ltd and has a patent US20190200915A1 pending to Hoffmann-La Roche Inc., a patent EP3701542A2 pending to F. Hoffmann-La Roche AG, a patent WO2019215230A1 pending to F. Hoffmann-La Roche AG, and a patent WO2021055443A1 pending to F. Hoffmann-La Roche AG.